Skip to main
AMPH
AMPH logo

Amphastar Pharma (AMPH) Stock Forecast & Price Target

Amphastar Pharma (AMPH) Analyst Ratings

Based on 6 analyst ratings
Hold
Strong Buy 17%
Buy 17%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Amphastar Pharmaceuticals Inc. has shown a positive sales trajectory with a ~20% quarter-over-quarter increase in Baqsimi prescriptions during the third quarter of 2025, supported by collaboration with MNKD and seasonal market trends. The company anticipates a return to double-digit growth in 2026, alongside expectations of high-single digit unit growth for its products in 2025, which positions it to potentially operate in line with industry peers regarding top-line performance and price-to-earnings ratios. Additionally, strong sales from products like Primatene Mist during the fall/winter season contribute to a favorable outlook for Amphastar's revenue growth and overall financial performance.

Bears say

Amphastar Pharmaceuticals Inc. is facing significant competitive pressures that are negatively impacting its revenue projections, particularly for iron sucrose and glucagon products, with estimated sales for iron sucrose expected to fall to approximately $5 million quarterly instead of the previously forecasted $60 million annually. The revenue forecast for glucagon is also deteriorating, with expectations for sales to decline below $70 million starting in 2026 due to increased market competition and the entry of multiple new players. Additionally, prospects for top-line growth have been revised down from double-digit growth to high-single digits to low-double digits, indicating a more cautious outlook for the company’s financial performance in the coming years.

Amphastar Pharma (AMPH) has been analyzed by 6 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 17% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amphastar Pharma (AMPH) Forecast

Analysts have given Amphastar Pharma (AMPH) a Hold based on their latest research and market trends.

According to 6 analysts, Amphastar Pharma (AMPH) has a Hold consensus rating as of Dec 17, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amphastar Pharma (AMPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.